Evaluating When and Why Patients Discontinue Chronic Therapy for Irritable Bowel Syndrome With Constipation and Chronic Idiopathic Constipation
نویسندگان
چکیده
منابع مشابه
Linaclotide (Linzess) for Irritable Bowel syndrome With Constipation and For Chronic Idiopathic Constipation.
Linaclotide (Linzess) for irritable bowel syndrome with constipation and for chronic idiopathic constipation.
متن کاملLinaclotide: a novel therapy for chronic constipation and constipation-predominant irritable bowel syndrome.
Chronic constipation and irritable bowel syndrome (IBS) are functional gastrointestinal disorders that significantly affect patients' quality of life. Chronic constipation and IBS are prevalent-1 2% of the US population meet the diagnostic criteria for IBS, and 1 5% meet the criteria for chronic constipation- and these conditions negatively impact the healthcare system from an economic perspect...
متن کاملEtiology and Pathophysiology of Irritable Bowel Syndrome and Chronic Constipation
Functional gastrointestinal (GI) disorders are collections of symptoms attributable to the GI tract in the absence of mucosal, structural, or biochemical disease. Two of the most common disorders, chronic constipation and irritable bowel syndrome (IBS), have common etiopathogenetic features—notably psychosocial disturbances, dysmotility, and heightened sensitivity. In some patients with IBS, th...
متن کاملRifaximin therapy for patients with irritable bowel syndrome without constipation.
BACKGROUND Evidence suggests that gut flora may play an important role in the pathophysiology of the irritable bowel syndrome (IBS). We evaluated rifaximin, a minimally absorbed antibiotic, as treatment for IBS. METHODS In two identically designed, phase 3, double-blind, placebo-controlled trials (TARGET 1 and TARGET 2), patients who had IBS without constipation were randomly assigned to eith...
متن کاملSafety and efficacy of tegaserod therapy in patients with irritable bowel syndrome or chronic constipation.
BACKGROUND Tegaserod, a 5-HT4 agonist, is effective for treating irritable bowel syndrome and chronic constipation. However, sales of this drug were recently suspended due to concerns about a higher rate of cardiovascular events in patients receiving tegaserod over placebo in clinical trials. Our aim was to review patients in our practice prescribed tegaserod to determine if any of them had suf...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Gastroenterology
سال: 2020
ISSN: 0002-9270,1572-0241
DOI: 10.14309/ajg.0000000000000530